Mounjaro‘s Meteoric Rise in India: A Glimpse into the Future of Weight Loss and Diabetes Management The Indian pharmaceutical landscape is witnessing a seismic shift. Mounjaro, Eli Lilly’s revolutionary drug for weight loss and diabetes, has exploded onto the scene. In just three months since its launch, sales have soared to Rs 24 crore, making … Read more
Philanthropy Fuels a Healthcare Revolution: The Future of Medical Innovation In a remarkable display of commitment to healthcare advancement, a $20 million donation from former Eli Lilly executives and their families has ignited a wave of optimism within the IU Health Foundation. This substantial gift, the largest in the foundation’s history, will establish the Institute … Read more
The Shifting Landscape of Weight Management The recent bankruptcy filing of WeightWatchers highlights a pivotal shift in the weight management industry. This change underscores a growing preference for wellness over traditional weight metrics, spurred by the rise of telehealth services and the impact of social media influencers. Telehealth Takes the Lead Adam McBride, CEO of … Read more
The Bitter Pill of Tariffs: Ireland’s Pharma Dilemma The picturesque town of Westport in County Mayo stands in stark contrast to its grey, factory-dominated skyline. These factories, chiefly producing Botox and other pharmaceuticals, form the economic backbone of Westport. Yet, President Donald Trump’s push for reshoring pharma production casts uncertainty over the 7,000 individuals dependent … Read more
The Future of Diabetes and Obesity Treatment: Eli Lilly‘s Leap with Orforglipron Shifting Paradigms in Diabetes and Obesity Management In the ever-evolving landscape of diabetes and obesity treatment, Eli Lilly has emerged as a frontrunner with its new oral weight-loss and diabetes drug, orforglipron. This promising drug stands out due to its impressive results in … Read more
Accelerated Launch of Pathbreaking Weight-Loss Drugs in India Danish pharmaceutical giant Novo Nordisk is strategizing an earlier-than-planned debut of its popular weight-loss drug, Wegovy, in India. This move aims to keep pace with U.S. competitor, Eli Lilly, whose diabetes and obesity drug, Mounjaro, has already seen its launch in the country. Novo, initially targeting 2026, … Read more
The Rise of Weight-Loss Pharmaceuticals in India The Indian pharmaceutical landscape is witnessing a significant transformation with the introduction of weight-loss drugs like Mounjaro by Eli Lilly & Co. This revolutionary drug, priced at ₹14,000 to ₹17,500 per month, is tailored for the Indian market, marking a competitive entry into the burgeoning sector of GLP-1 … Read more
The Future of Weight-Loss Treatments: Transitioning from Injections to Pills The landscape of weight-loss treatments is undergoing a significant transformation. Companies like Eli Lilly are pioneering efforts to make GLP-1 treatments more accessible worldwide with the introduction of an oral pill, orforglipron. This shift from injections to oral medications promises broader reach and adoption, according … Read more